{"id":"remsima","rwe":[],"tags":[],"trials":[],"_chembl":null,"aliases":[],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":null,"ecosystem":[],"_scrapedAt":"2026-03-28T00:04:43.854Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT03819296","phase":"PHASE1","title":"Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-02-21","conditions":"Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8","enrollment":800},{"nctId":"NCT04407247","phase":"PHASE1, PHASE2","title":"Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-07-09","conditions":"Colitis, Lung Non-Small Cell Carcinoma, Malignant Genitourinary System Neoplasm","enrollment":47},{"nctId":"NCT02829424","phase":"PHASE4","title":"Multicenter Randomized Double Blind Controlled-study to Assess the Potential of Methotrexate Versus Placebo to Improve and Maintain Response to Anti TNF- Alpha Agents in Adult Patients With Moderate to Severe Psoriasis","status":"TERMINATED","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2017-01-23","conditions":"Psoriasis","enrollment":78},{"nctId":"NCT04898231","phase":"PHASE2, PHASE3","title":"MIS-C Comparative Effectiveness Study","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2020-12-22","conditions":"Multisystem Inflammatory Syndrome-Children","enrollment":73},{"nctId":"NCT05424926","phase":"","title":"Sub-cutaneous Infliximab in Inflammatory Rheumatic Disease","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-02-24","conditions":"Rheumatoid Arthritis, Spondyloarthritis, Psoriatic Arthritis","enrollment":22},{"nctId":"NCT07120152","phase":"","title":"A Pharmacokinetic-pharmacodynamic Modeling and Simulation Study of Subcutaneous Infliximab in Patients With Inflammatory Bowel Disease","status":"NOT_YET_RECRUITING","sponsor":"Erwin Dreesen","startDate":"2025-09-01","conditions":"IBD - Inflammatory Bowel Disease, RA - Rheumatoid Arthritis","enrollment":439},{"nctId":"NCT03011268","phase":"NA","title":"Anti-tumor Necrosis Factor in Patients With Ulcerative Colitis in Clinical Remission: to Continue or Not?","status":"COMPLETED","sponsor":"Helse Møre og Romsdal HF","startDate":"2017-06-09","conditions":"Colitis,Ulcerative","enrollment":174},{"nctId":"NCT03681652","phase":"","title":"Post-Operative Crohn's Disease Outcome in Children","status":"RECRUITING","sponsor":"Schneider Children's Medical Center, Israel","startDate":"2019-02-11","conditions":"Crohn Disease","enrollment":100},{"nctId":"NCT05722353","phase":"NA","title":"IBD Disease Course of Infliximab-naïve IBD Patients Treated With Subcutaneous Infliximab CT-P13 Remsima®","status":"ACTIVE_NOT_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-02-13","conditions":"Inflammatory Bowel Diseases","enrollment":120},{"nctId":"NCT03937609","phase":"PHASE4","title":"TITRATE (inducTIon for acuTe ulceRATivE Colitis)","status":"TERMINATED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2019-09-04","conditions":"Colitis, Ulcerative","enrollment":50},{"nctId":"NCT04646187","phase":"PHASE4","title":"De-escalation of Anti-TNF Therapy in Inflammatory Bowel Disease","status":"ENROLLING_BY_INVITATION","sponsor":"University Medical Center Groningen","startDate":"2021-03-11","conditions":"Inflammatory Bowel Diseases, Crohn Disease, Colitis, Ulcerative","enrollment":148},{"nctId":"NCT06059989","phase":"PHASE3","title":"InDuctIon TREatment with SubCuTaneous Infliximab for Crohn's Disease","status":"RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2021-11-25","conditions":"Inflammatory Disease, Disease Crohn, Bowel Disease","enrollment":158},{"nctId":"NCT02557308","phase":"","title":"An Observational Study to Evaluate Safety and Efficacy of Remsima™ in Patients With Ankylosing Spondylitis","status":"TERMINATED","sponsor":"Celltrion","startDate":"2015-05-26","conditions":"Ankylosing Spondylitis","enrollment":329},{"nctId":"NCT02557295","phase":"","title":"An Observational Study to Evaluate Safety and Efficacy of Remsima™ in Patients With RA","status":"TERMINATED","sponsor":"Celltrion","startDate":"2013-12-17","conditions":"Rheumatoid Arthritis","enrollment":248},{"nctId":"NCT06591273","phase":"PHASE1, PHASE2","title":"Efficacy and Safety of Infliximab Biosimilar in Treatment of Moderate to Severe Psoriasis; A Single-arm Clinical Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Services Institute of Medical Sciences, Pakistan","startDate":"2023-11-06","conditions":"Moderate to Severe Chronic Plaque Psoriasis","enrollment":104},{"nctId":"NCT05866614","phase":"","title":"A Study to Evaluate the Safety of Remsima® SC in the Treatment of RA, AS, PsA and Ps","status":"RECRUITING","sponsor":"Celltrion","startDate":"2023-01-13","conditions":"Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis","enrollment":864},{"nctId":"NCT06064864","phase":"NA","title":"Efficacy and Safety of Formulation Switching Between SC Infliximab and IV Infliximab in Patients With CD","status":"RECRUITING","sponsor":"Asan Medical Center","startDate":"2023-10-09","conditions":"Crohn's Disease","enrollment":100},{"nctId":"NCT04990258","phase":"","title":"A 24-month Real Life PErsistence Efficacy and Safety Study in IBD Patients in REMission Switched From Intravenous Infliximab to Subcutaneous Infliximab CT-P13 Remsima®SC","status":"UNKNOWN","sponsor":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives","startDate":"2021-09-06","conditions":"Inflammatory Bowel Diseases","enrollment":444},{"nctId":"NCT05663268","phase":"EARLY_PHASE1","title":"Efficacy and Safety of Infliximab Biosimilar in the Treatment of Resistant Hidradenitis Suppurativa","status":"COMPLETED","sponsor":"Services Institute of Medical Sciences, Pakistan","startDate":"2022-10-01","conditions":"Hidradenitis Suppurativa","enrollment":37},{"nctId":"NCT06043752","phase":"PHASE4","title":"Efficacy and Safety of Infliximab Biosimilar Remsima in Psoriasis","status":"COMPLETED","sponsor":"Ghurki Trust and Teaching Hospital","startDate":"2022-03-10","conditions":"Psoriasis","enrollment":51},{"nctId":"NCT05584228","phase":"NA","title":"Medical Treatment Versus Surgery in Stricturing Small Bowel Crohn's Disease","status":"NOT_YET_RECRUITING","sponsor":"Nantes University Hospital","startDate":"2023-04-01","conditions":"Crohn Disease","enrollment":150},{"nctId":"NCT05072782","phase":"PHASE4","title":"Management of Moderate POstoperative Recurrence in Crohn's Disease: a randoMizEd contROLled Trial of Therapeutic Escalation, the POMEROL Trial. (POMEROL)","status":"UNKNOWN","sponsor":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives","startDate":"2021-12-21","conditions":"Crohn Disease","enrollment":360},{"nctId":"NCT05379049","phase":"","title":"Therapeutic Response to Tumor Necrosis Factor-alpha (TNF-alpha) Antagonists in Rheumatoid Arthritis.","status":"UNKNOWN","sponsor":"University of Sulaimani","startDate":"2022-03-01","conditions":"Rheumatoid Arthritis, Inflammatory Arthritis, Ankylosing Spondylitis","enrollment":80},{"nctId":"NCT02326155","phase":"","title":"To Evaluate the Safety and Efficacy of Remsima™ in Patients With Crohn's Disease (CD) or Ulcerative Colitis (UC)","status":"TERMINATED","sponsor":"Celltrion","startDate":"2014-12-08","conditions":"Crohn's Disease, Ulcerative Colitis","enrollment":470},{"nctId":"NCT05164198","phase":"PHASE4","title":"REduCed Dose of TNFi in Patients With Ankylosing SpondyliTis (RECAST)","status":"UNKNOWN","sponsor":"Hanyang University Seoul Hospital","startDate":"2022-01-15","conditions":"Ankylosing Spondylitis, Axial Spondyloarthritis","enrollment":448},{"nctId":"NCT05051137","phase":"","title":"Real-World Emulation of the SWEFOT Trial","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2006-01-12","conditions":"Rheumatoid Arthritis","enrollment":509},{"nctId":"NCT03452501","phase":"","title":"Safety and Effectiveness Study of Remsima® in the Treatment of Inflammatory Bowel Diseases Among Saudi Arabia Patients","status":"COMPLETED","sponsor":"Hikma Pharmaceuticals LLC","startDate":"2018-08-26","conditions":"Inflammatory Bowel Diseases, Crohn Disease, Fistulizing Crohn's Disease","enrollment":157},{"nctId":"NCT03348046","phase":"","title":"Safety Study of Remsima® (Infliximab) in Rheumatoid Arthritis Patients in Jordan","status":"COMPLETED","sponsor":"Hikma Pharmaceuticals LLC","startDate":"2017-03-23","conditions":"Rheumatoid Arthritis","enrollment":22},{"nctId":"NCT02539368","phase":"","title":"Post-Marketing Use Of CT-P13 (Infliximab) For Standard Of Care Treatment Of Inflammatory Bowel Disease","status":"COMPLETED","sponsor":"Pfizer","startDate":"2015-04-22","conditions":"Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn's Disease","enrollment":2565},{"nctId":"NCT02605642","phase":"","title":"Post-Marketing Use Of CT-P13 (Infliximab) For Standard Of Care Treatment Of Rheumatoid Diseases Who Are Naïve To Biologics Or Switched From Remicade","status":"COMPLETED","sponsor":"Pfizer","startDate":"2015-09-10","conditions":"Rheumatoid Diseases, Rheumatoid Arthritis, Ankylosing Spondylitis","enrollment":351},{"nctId":"NCT03016260","phase":"","title":"RABIOPRED - a Validation Study of Theranostic Test to PREDict Treatment Response of Anti-TNFα BIologicals in Rheumatoid Arthritis","status":"TERMINATED","sponsor":"TcLand Expression S.A.","startDate":"2016-12","conditions":"RheumatoId Arthritis","enrollment":250},{"nctId":"NCT03108326","phase":"","title":"Real World Effectiveness of Ustekinumab in Induction and Maintenance Therapy for Crohn´s Disease","status":"UNKNOWN","sponsor":"Ced Service GmbH","startDate":"2017-04-15","conditions":"Crohn Disease","enrollment":900},{"nctId":"NCT02148640","phase":"PHASE4","title":"The NOR-SWITCH Study","status":"COMPLETED","sponsor":"Diakonhjemmet Hospital","startDate":"2014-10","conditions":"Rheumatoid Arthritis, Spondyloarthritis, Psoriatic Arthritis","enrollment":482},{"nctId":"NCT02457585","phase":"PHASE2","title":"Clinical Study of Anti-tumor Necrosis Factor Therapy in Patients With Takayasu Arteritis","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2015-03","conditions":"Takayasu's Arteritis","enrollment":11}],"_emaApprovals":[],"_faersSignals":[{"count":142,"reaction":"DYSPNOEA"},{"count":106,"reaction":"OFF LABEL USE"},{"count":81,"reaction":"DRUG INEFFECTIVE"},{"count":60,"reaction":"OVERDOSE"},{"count":59,"reaction":"UNDERDOSE"},{"count":53,"reaction":"ERYTHEMA"},{"count":53,"reaction":"MALAISE"},{"count":52,"reaction":"INAPPROPRIATE SCHEDULE OF DRUG ADMINISTRATION"},{"count":51,"reaction":"HEADACHE"},{"count":48,"reaction":"ARTHRALGIA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":95,"therapeuticAreas":["Other"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Remsima","genericName":"Remsima","companyName":"Ghurki Trust and Teaching Hospital","companyId":"ghurki-trust-and-teaching-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}